Evidence map›Paper›PMID 42419819›Full record

ArticleBMJ open respiratory research2026

Primary Care Integrated Management of chronic obstructive pulmonary disease (PRIM-COPD): study protocol for a cluster-randomised controlled trial.

Yiwen Yu, Xiaoxia Ren, Xu Chu, Jisong Yan, Feng Guo, Quan Wan, Ke Huang, Jieping Lei, Xingyao Tang, Xing Qi and 7 more

Registry-linked trialAbstract read
In one paragraph

Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06573580 (Pilot Project for the Primary Health Management of Chronic Obstructive Pulmonary Disease), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06573580 naactive not recruitingnot on this map

Pilot Project for the Primary Health Management of Chronic Obstructive Pulmonary Disease

TypeinterventionalSponsorChina-Japan Friendship HospitalRan2024 to 2025Enrolled6,000ConditionsPulmonary Disease, Chronic Obstructive Pulmonary DiseaseArmsThe essential public health service(EPHS)for COPD
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yiwen Yu *School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID http://orcid.org/0000-0002-3935-846X
Xiaoxia Ren *Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Beijing, China.
Xu Chu *Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Beijing, China.
Jisong YanDepartment of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Beijing, China.
Feng GuoChina National Health Development Research Center, Beijing, China.
Quan WanChina National Health Development Research Center, Beijing, China.
Ke HuangChina National Health Development Research Center, Beijing, China.ORCID http://orcid.org/0000-0001-8933-387X
Jieping LeiData and Project Management Unit, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
Xingyao TangDepartment of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Beijing, China.
Xing QiDepartment of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Beijing, China.
Junsheng ZhengDepartment of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Beijing, China.
Yong LiDepartment of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Beijing, China.
Fang FangGeneral Office of North Campus, China-Japan Friendship Hospita, Beijing, China.
Jun PanGeneral Office, China-Japan Friendship Hospital, Beijing, China.
Cunbo JiaGeneral Office, China-Japan Friendship Hospital, Beijing, China.
Ting YangDepartment of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Beijing, China zryyyangting@163.com.
Chen WangSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, with China bearing a particularly high burden. Major gaps persist in early diagnosis, guideline-based treatment and long-term disease management, especially in primary care. This study aims to evaluate the efficacy and feasibility of the National Essential Public Health Services (NEPHS) COPD management approach and to generate evidence to inform the optimisation of national COPD care standards. METHODS AND ANALYSIS: The Primary Care Integrated Management (PRIM) trial is a prospective, multicentre, cluster-randomised controlled study conducted in seven pilot regions in China, with primary healthcare institutions as the unit of randomisation. Participants are adults aged ≥35 years with spirometry-confirmed COPD, recruited either through screening or from existing patient databases. Institutions will be randomised in a 1:1 ratio to the intervention (PRIM) or usual care arms using a computer-generated allocation sequence, stratified by urban-rural location. The intervention comprises quarterly general practitioner (GP)-led follow-ups, health education and disease management according to pilot NEPHS COPD guidelines, supported by a three-tier oversight structure involving the National Center for Respiratory Medicine, leading tertiary hospitals and primary healthcare institutions. Co-primary outcomes are the annual number of acute exacerbations and health-related quality of life (European Quality of Life-5 Dimensions and 5 Levels). Secondary outcomes include smoking status, health status assessed by the COPD Assessment Test (CAT), dyspnoea score and GP knowledge. Analyses will follow the intention-to-treat principle, using multivariable regression models adjusted for clustering and prespecified baseline covariates. Cost-effectiveness analyses of the PRIM intervention in the Chinese population are also planned. ETHICS AND DISSEMINATION: Ethics approval has been granted by China-Japan Friendship Hospital (approval number 2024-KY-163). TRIAL REGISTRATION NUMBER: NCT06573580.

Indexed as

Delivery of Health Care, IntegratedPrimary Health CarePulmonary Disease, Chronic ObstructiveAdultAgedChinaDisease ManagementFemaleHumansMaleMiddle AgedMulticenter Studies as TopicPilot ProjectsProspective StudiesQuality of LifeRandomized Controlled Trials as TopicCOPD Exacerbations

Identifiers

PMID42419819
PMCPMC13347819

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.